5,180 reports of this reaction
3.1% of all CLOPIDOGREL BISULFATE reports
#1 most reported adverse reaction
DYSPNOEA is the #1 most commonly reported adverse reaction for CLOPIDOGREL BISULFATE, manufactured by Apotex Corp.. There are 5,180 FDA adverse event reports linking CLOPIDOGREL BISULFATE to DYSPNOEA. This represents approximately 3.1% of all 168,674 adverse event reports for this drug.
Patients taking CLOPIDOGREL BISULFATE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among CLOPIDOGREL BISULFATE users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for CLOPIDOGREL BISULFATE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 5,180 FDA reports for CLOPIDOGREL BISULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.1% of all adverse event reports for CLOPIDOGREL BISULFATE, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking CLOPIDOGREL BISULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.